SAN MATEO, Calif., Oct. 6, 2015 /PRNewswire/ — Maverix Biomics, Inc., a leading genomic analysis software company, today announced enhancements to its software portfolio with the debut of its RNA-Seq 3.0 gene expression analysis kit for differential expression in eukaryotes. The software is integrated into the Maverix Analytic Platform, which is a cloud-based genomic analysis solution that leverages proven open-source algorithms and applications to advance scientific discovery from next-generation sequencing efforts.
Dr. Garry Nolan’s laboratory at Stanford University has been using the Maverix RNASeq analysis kit to facilitate a deeper understanding of normal immune function, detailed substructures of cancer, auto-immunity, and pathogen effects upon the immune system. Postdoctoral fellow, Dr. Felice Alessio Bava, believes that the new kit has advanced his work in the study of epigenetic control of RNA signatures in cancer.
“As labs integrate various ‘omics disciplines, they must rapidly master new tools. The Maverix RNA-Seq software suite gave RNA experts in my lab—and even those new to the area—an accessible integrated “home” where workflows and analysis were managed through an intuitive interface. No more command line slash alphabet soup,” stated Dr. Nolan. “Welcome to the 21st Century for RNASeq analysis!”
Dr. Bava stated, “The Maverix RNA-Seq analysis kit saved us considerable time and effort, and provided us with accurate and insightful analyses that have aided our cancer studies. And, the Maverix platform is very easy for scientists to learn and use.”
Enhancements in the RNA-Seq 3.0 version include optimization for high throughput large-scale analysis projects, additional differential expression analysis tools, methods for the exploration of patterns in data, and support for more organisms, which now includes human, numerous animal models, plants, and fungi. And, the new “1-2-3-Launch” user experience, unique to Maverix analysis kits, makes it very simple for scientists, even without bioinformatics experience, to perform complex genomic analyses, and obtain meaningful results.
The Maverix mRNA-Seq analysis pipeline applies open-source tools, including a spliceaware aligner (either TopHat or STAR), in conjunction with differential expression analysis tools (Cufflinks, DESeq, and edgeR), to elucidate the transcriptome and analyze differential expression. Analysis results are provided through a variety of visual representations, including charts and tables, gene and sample correlation heatmaps, PCA scatter plots and histograms, and interactive heatmaps linked to a private version of the UCSC Genome Browser.
“Delivering the substantial improvements in our new RNA-Seq analysis kit demonstrates our commitment to the continuing development of our genomic and transcriptomic analysis solutions,” said Tom Kent, President of Maverix Biomics. “We are pleased that world renowned scientists are utilizing our technology to advance research that will ultimately have a positive impact on the understanding of devastating diseases, such as cancer.”
Maverix also provides analysis kits for Germline Variant Analysis, Somatic Variant Analysis, and Small RNA-Seq. And, Maverix supports a wide range of organisms, including human, animal models, Arabidopsis, and a variety of microorganisms.
About the Maverix Analytic Platform
The Maverix Analytic Platform is a cloud-based solution designed for use directly by life sciences researchers who may not have software or bioinformatics expertise. It leverages proven open-source algorithms and applications developed at leading academic and research centers. After loading sequence data from any organism (human, animal, plant, or microbe), researchers are able to immediately perform analyses with reliable, scientifically vetted configurations, as cited in peer-reviewed journal publications. Visualizations are provided through a variety of integrated graphical tools, including a private, secure version of the UCSC Genome Browser, the world’s most widely used genome browser.
About Maverix Biomics
Based in San Mateo, CA and backed by leading venture capital firms and Silicon Valley investors, Maverix Biomics, Inc. provides researchers with a cloud-based platform to manage, analyze, and visualize genomic data, build Communities of Discovery, and place their data in context with the latest public data from the full spectrum of life, including human, plant, animal, or microorganisms. For more information, visit www.maverixbio.com.
SOURCE – Maverix Biomics, Inc.